From the Nothing About Us. Without Us thread.
Another COVID Study
"Zureik, Baricault, Vabre, Semenzato, Drouin, Cuenot, Penso, Herlemont, Sbidian, Weill, Molimard, Dray-Spira, and Botton collaborated on a study looking at the use of nicotine-replacement therapy (NRT) as a stop smoking treatment, and how that related to a risk of hospitalisation with viral symptoms, or possible death from Covid-19.
...
For each exposed individual, they selected two non-exposed French people from the population at random. They were matched up for age, sex, area of residence, and that they held similar health insurance (so would ideally receive the same treatment).
The end points they looked at were either entry to hospital with COVID-19 symptoms, death or being placed on a ventilator in hospital while diagnosed with COVID-19, and all-cause mortality. They then compared the outcomes of individuals using NRT with those who didn’t.
...
During the four months of the study, 647 patients were admitted to hospital with a COVID diagnosis. This broke down as 151 NRT users and 496 non-NRT patients.
They write: “In the main multivariable analysis, nicotine-replacement therapy was associated with a decreased risk of hospitalization with Covid-19 compared with unexposed individuals. Nicotine-replacement therapy exposure was also associated with a decreased risk of intubation or death in hospitalized individuals with Covid-19 but with an increased risk of all-cause mortality.”
...
The researchers conducted a second analysis. This time they looked at 128,768 NRT users with major smoking-related diseases, matched with 243,793 random non-NRT individuals. The average person was slightly older and more likely to be male than the previous analysis.
They state: “In the main multivariable analysis, nicotine-replacement therapy exposure was neither associated with risk of hospitalisation with Covid-19 nor with risk of death or an intubation in hospitalized individuals with Covid-19.”
Dying from any cause was predictably higher in the NRT/smoking-related diseases group.
They concluded: “This large-scale observational study suggests that smoking, measured by exposure to nicotine-replacement therapy, was associated with an increased risk of overall mortality during the first wave of SARS-CoV-2 epidemic in France, although it was associated with a lower risk of severe Covid-19 in individuals without major related-smoking diseases.”
The authors add that further investigation needs to be conducted, “to disentangle the potential mechanisms of nicotine and/or smoking in Covid-19 risk. Whatever the nature of these associations, the global impact of smoking is harmful for health even over a short epidemic period.”"
Another COVID Study
"Zureik, Baricault, Vabre, Semenzato, Drouin, Cuenot, Penso, Herlemont, Sbidian, Weill, Molimard, Dray-Spira, and Botton collaborated on a study looking at the use of nicotine-replacement therapy (NRT) as a stop smoking treatment, and how that related to a risk of hospitalisation with viral symptoms, or possible death from Covid-19.
...
For each exposed individual, they selected two non-exposed French people from the population at random. They were matched up for age, sex, area of residence, and that they held similar health insurance (so would ideally receive the same treatment).
The end points they looked at were either entry to hospital with COVID-19 symptoms, death or being placed on a ventilator in hospital while diagnosed with COVID-19, and all-cause mortality. They then compared the outcomes of individuals using NRT with those who didn’t.
...
During the four months of the study, 647 patients were admitted to hospital with a COVID diagnosis. This broke down as 151 NRT users and 496 non-NRT patients.
They write: “In the main multivariable analysis, nicotine-replacement therapy was associated with a decreased risk of hospitalization with Covid-19 compared with unexposed individuals. Nicotine-replacement therapy exposure was also associated with a decreased risk of intubation or death in hospitalized individuals with Covid-19 but with an increased risk of all-cause mortality.”
...
The researchers conducted a second analysis. This time they looked at 128,768 NRT users with major smoking-related diseases, matched with 243,793 random non-NRT individuals. The average person was slightly older and more likely to be male than the previous analysis.
They state: “In the main multivariable analysis, nicotine-replacement therapy exposure was neither associated with risk of hospitalisation with Covid-19 nor with risk of death or an intubation in hospitalized individuals with Covid-19.”
Dying from any cause was predictably higher in the NRT/smoking-related diseases group.
They concluded: “This large-scale observational study suggests that smoking, measured by exposure to nicotine-replacement therapy, was associated with an increased risk of overall mortality during the first wave of SARS-CoV-2 epidemic in France, although it was associated with a lower risk of severe Covid-19 in individuals without major related-smoking diseases.”
The authors add that further investigation needs to be conducted, “to disentangle the potential mechanisms of nicotine and/or smoking in Covid-19 risk. Whatever the nature of these associations, the global impact of smoking is harmful for health even over a short epidemic period.”"
